June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Bezafibrate downregulates the retinal microvascular inflammation.
Author Affiliations & Notes
  • Ayumi Usui
    Ophthalmology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Jersey
  • Nobuyuki Ebihara
    Ophthalmology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Jersey
  • Footnotes
    Commercial Relationships   Ayumi Usui, None; Nobuyuki Ebihara, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5793. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ayumi Usui, Nobuyuki Ebihara; Bezafibrate downregulates the retinal microvascular inflammation.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5793.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Bezafibrate (BZF) is a fibrate drug used as a lipid-lowering agent to treat hyperlipidemia. The results of randomized clinical trial have shown the beneficial effects of systemic fenofibrate therapy in reducing the progression of diabetic retinopathy independently of serum lipid levels. BZF is a pan-agonist for all subtypes of peroxisome proliferator-activated receptor (PPAR) such as PPARα, PPARγ, and PPARβ/δ. It has been reported PPARs play a key role in microvascular inflammation or angiogenesis. However, the effects of BZF in retinal cells remain unclear. The purpose of this study is to investigate the effects of BZF on retinal microvascular inflammation.

Methods : The primary human microvascular endothelial cells (HRMECs) and human RPE cell line (ARPE-19) were cultured. First, cytotoxicity and cell viability of BZF were assessed by CCK-8 assay and LDH activity assay. Next, we analyzed the effect of BZF(0,30,100μM) treatment on the expression of TNF-α–induced monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in HRMECs by real-time PCR and ELISA. And we analyzed the nuclear translocation of NFκB p65 subunit in BZF-treated HRMECs using TransAM NFκB kit® (Active Motif). IL-1β-induced Vascular Endothelial Growth Factor (VEGF) production in ARPE-19 was analyzed by real-time PCR and ELISA.

Results : The cytotoxicity was significantly increased in HRMECs and ARPE-19 by treating with more than 200μM and 500μM of BZF, respectively. In HRMECs, the expression of TNF-α-induced MCP-1, ICAM-1 and VCAM-1 was significantly suppressed by BZF in a dose-dependent manner. TNF-α-induced nuclear translocation of NFκB p65 in HRMECs was also significantly decreased by BZF (p<0.01). Furthermore, IL1-β-induced VEGF production in RPE cells was also suppressed by BZF (p<0.01).

Conclusions : It is suggested that BZF has beneficial effects on retinal microvascular inflammation in the pathogenesis of diabetic retinopathy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×